Dr. Hildebrandt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
One Hospital Drive
Columbia, MO 65212Phone+1 573-882-8445Fax+1 573-884-6292
Education & Training
- Johannes Gutenberg University of Mainz Faculty of MedicineClass of 1997
Certifications & Licensure
- MO State Medical License 2022 - 2026
- KY State Medical License 2014 - 2025
- LA State Medical License 2009 - 2017
- UT State Medical License 2012 - 2015
Clinical Trials
- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Publications & Presentations
PubMed
- 1 citationsChemotherapy-induced acceleration of DNA methylation-based biological age in breast cancer.Drew R Nannini, Rene Cortese, Christopher VonTungeln, Gerhard C Hildebrandt
Epigenetics. 2024-12-01 - 1 citationsLate effects after allogeneic haematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study.Justine Kahn, Ruta Brazauskas, Stephanie Bo-Subait, David Buchbinder, Betty K Hamilton
The Lancet. Child & Adolescent Health. 2024-10-01 - Inhibiting AGTR1 reduces AML burden and protects the heart from cardiotoxicity in mouse models.Yi Pan, Chen Wang, WenXuan Zhou, Yao Shi, XiaDuo Meng
Science Translational Medicine. 2024-06-19
Journal Articles
- Age Adjusted Hematopoietic Stem Cell Transplant Comorbidity Index Predicts Survival in a T-cell Depleted Cohort☆Swati Yalamanchi, Hayder Saeed, Dianna Howard, Gerhard C Hildebrandt, Roger Herzig, Gregory Monohan, ScienceDirect
Abstracts/Posters
- Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial ...Gerhard C. Hildebrandt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Disparities in Plasma Cell Neoplasms in Kentucky, Appalachia and Other States: A Population Based StudyGerhard C. Hildebrandt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Includi...Gerhard C. Hildebrandt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
- Ellis Fischel Cancer Center Becomes AACI’s Newest MemberDecember 27th, 2022
- Siteman to Collaborate with University of Missouri on Cancer Research, with Aim to Improve CareSeptember 20th, 2022
- Researchers Discover Potential Treatments for Common Complication Following Bone Marrow TransplantFebruary 15th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: